88.73 USD
+1.32 (+1.51%)
88.73 USD
0 (0%)
Taking everything into account, PTGX scores 5 out of 10 in our fundamental rating. PTGX was compared to 530 industry peers in the Biotechnology industry. PTGX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PTGX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
In the past year PTGX was profitable.
In the past year PTGX had a positive cash flow from operations.
In the past 5 years PTGX reported 4 times negative net income.
In the past 5 years PTGX reported 4 times negative operating cash flow.
1.2 Ratios
PTGX has a Return On Assets of 6.54%. This is amongst the best in the industry. PTGX outperforms 92.26% of its industry peers.
PTGX has a Return On Equity of 7.11%. This is amongst the best in the industry. PTGX outperforms 91.13% of its industry peers.
PTGX's Return On Invested Capital of 2.29% is amongst the best of the industry. PTGX outperforms 89.62% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 7.11% | ||
| ROIC | 2.29% |
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of PTGX (21.94%) is better than 94.15% of its industry peers.
PTGX has a Operating Margin of 9.09%. This is amongst the best in the industry. PTGX outperforms 91.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.09% | ||
| PM (TTM) | 21.94% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PTGX is destroying value.
PTGX has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PTGX has been increased compared to 5 years ago.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PTGX has an Altman-Z score of 59.63. This indicates that PTGX is financially healthy and has little risk of bankruptcy at the moment.
PTGX has a Altman-Z score of 59.63. This is amongst the best in the industry. PTGX outperforms 97.17% of its industry peers.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 59.63 |
ROIC/WACC0.26
WACC8.81%
2.3 Liquidity
PTGX has a Current Ratio of 13.05. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
PTGX has a better Current ratio (13.05) than 88.68% of its industry peers.
PTGX has a Quick Ratio of 13.05. This indicates that PTGX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of PTGX (13.05) is better than 88.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 13.05 | ||
| Quick Ratio | 13.05 |
3. Growth
3.1 Past
The earnings per share for PTGX have decreased strongly by -76.69% in the last year.
Looking at the last year, PTGX shows a very negative growth in Revenue. The Revenue has decreased by -35.39% in the last year.
Measured over the past years, PTGX shows a very strong growth in Revenue. The Revenue has been growing by 352.10% on average per year.
EPS 1Y (TTM)-76.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.81%
Revenue 1Y (TTM)-35.39%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%0.79%
3.2 Future
The Earnings Per Share is expected to decrease by -1.37% on average over the next years.
Based on estimates for the next years, PTGX will show a small growth in Revenue. The Revenue will grow by 7.84% on average per year.
EPS Next Y-146.53%
EPS Next 2Y-42.59%
EPS Next 3Y-32.08%
EPS Next 5Y-1.37%
Revenue Next Year-79.29%
Revenue Next 2Y-10.26%
Revenue Next 3Y-15.89%
Revenue Next 5Y7.84%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 143.11, the valuation of PTGX can be described as expensive.
Based on the Price/Earnings ratio, PTGX is valued cheaper than 89.06% of the companies in the same industry.
When comparing the Price/Earnings ratio of PTGX to the average of the S&P500 Index (26.50), we can say PTGX is valued expensively.
The Forward Price/Earnings Ratio is negative for PTGX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 143.11 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, PTGX is valued cheaply inside the industry as 89.06% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, PTGX is valued cheaply inside the industry as 91.70% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 87.07 | ||
| EV/EBITDA | 220.5 |
4.3 Compensation for Growth
A cheap valuation may be justified as PTGX's earnings are expected to decrease with -32.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-42.59%
EPS Next 3Y-32.08%
5. Dividend
5.1 Amount
PTGX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
88.73
+1.32 (+1.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners113.72%
Inst Owner Change-0.12%
Ins Owners1.01%
Ins Owner Change-1.61%
Market Cap5.55B
Revenue(TTM)209.22M
Net Income(TTM)45.91M
Analysts85
Price Target96.12 (8.33%)
Short Float %9.68%
Short Ratio4.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.83%
Min EPS beat(2)4.88%
Max EPS beat(2)6.78%
EPS beat(4)4
Avg EPS beat(4)133.89%
Min EPS beat(4)4.88%
Max EPS beat(4)504.52%
EPS beat(8)8
Avg EPS beat(8)266.75%
EPS beat(12)10
Avg EPS beat(12)179.39%
EPS beat(16)14
Avg EPS beat(16)139.25%
Revenue beat(2)1
Avg Revenue beat(2)3.47%
Min Revenue beat(2)-20.11%
Max Revenue beat(2)27.04%
Revenue beat(4)2
Avg Revenue beat(4)57.59%
Min Revenue beat(4)-20.11%
Max Revenue beat(4)232.24%
Revenue beat(8)5
Avg Revenue beat(8)57.26%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)22.15%
PT rev (3m)35.85%
EPS NQ rev (1m)1.22%
EPS NQ rev (3m)-1.4%
EPS NY rev (1m)3.3%
EPS NY rev (3m)3.17%
Revenue NQ rev (1m)-65.91%
Revenue NQ rev (3m)40.29%
Revenue NY rev (1m)4.35%
Revenue NY rev (3m)45.14%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 143.11 | ||
| Fwd PE | N/A | ||
| P/S | 26.52 | ||
| P/FCF | 87.07 | ||
| P/OCF | 84.73 | ||
| P/B | 8.59 | ||
| P/tB | 8.59 | ||
| EV/EBITDA | 220.5 |
EPS(TTM)0.62
EY0.7%
EPS(NY)-0.14
Fwd EYN/A
FCF(TTM)1.02
FCFY1.15%
OCF(TTM)1.05
OCFY1.18%
SpS3.35
BVpS10.32
TBVpS10.32
PEG (NY)N/A
PEG (5Y)N/A
Graham Number12
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 6.54% | ||
| ROE | 7.11% | ||
| ROCE | 2.89% | ||
| ROIC | 2.29% | ||
| ROICexc | 18.62% | ||
| ROICexgc | 18.62% | ||
| OM | 9.09% | ||
| PM (TTM) | 21.94% | ||
| GM | N/A | ||
| FCFM | 30.45% |
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 121.94% | ||
| Cap/Sales | 0.84% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 320.17% | ||
| Profit Quality | 138.78% | ||
| Current Ratio | 13.05 | ||
| Quick Ratio | 13.05 | ||
| Altman-Z | 59.63 |
F-Score5
WACC8.81%
ROIC/WACC0.26
Cap/Depr(3y)47.62%
Cap/Depr(5y)67.63%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-14.81%
EPS Next Y-146.53%
EPS Next 2Y-42.59%
EPS Next 3Y-32.08%
EPS Next 5Y-1.37%
Revenue 1Y (TTM)-35.39%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%0.79%
Revenue Next Year-79.29%
Revenue Next 2Y-10.26%
Revenue Next 3Y-15.89%
Revenue Next 5Y7.84%
EBIT growth 1Y-87.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-196.54%
EBIT Next 3Y-32.74%
EBIT Next 5YN/A
FCF growth 1Y153.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y155.09%
OCF growth 3YN/A
OCF growth 5YN/A
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
Can you provide the ChartMill fundamental rating for PROTAGONIST THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to PTGX.
Can you provide the valuation status for PROTAGONIST THERAPEUTICS INC?
ChartMill assigns a valuation rating of 3 / 10 to PROTAGONIST THERAPEUTICS INC (PTGX). This can be considered as Overvalued.
How profitable is PROTAGONIST THERAPEUTICS INC (PTGX) stock?
PROTAGONIST THERAPEUTICS INC (PTGX) has a profitability rating of 4 / 10.
Can you provide the financial health for PTGX stock?
The financial health rating of PROTAGONIST THERAPEUTICS INC (PTGX) is 8 / 10.
Can you provide the expected EPS growth for PTGX stock?
The Earnings per Share (EPS) of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to decline by -146.53% in the next year.